Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response

por Bibeau, Kristen, Féliz, Luis, Lihou, Christine F., Ren, Haobo, Abou-Alfa, Ghassan K.
Publicado 2022

FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies

por Fujiwara, Yutaka, Kuboki, Yasutoshi, Furukawa, Masayuki, Mizuno, Nobumasa, Hara, Hiroki, Ioka, Tatsuya, Ueno, Makoto, Takahashi, Yasuo, Takahashi, Shunji, Takeuchi, Shinji, Lihou, Christine, Ji, Tao, Tian, Chenwei, Shimizu, Toshio
Publicado 2023

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

por Bekaii-Saab, Tanios S, Valle, Juan W, Cutsem, Eric Van, Rimassa, Lorenza, Furuse, Junji, Ioka, Tatsuya, Melisi, Davide, Macarulla, Teresa, Bridgewater, John, Wasan, Harpreet, Borad, Mitesh J, Abou-Alfa, Ghassan K, Jiang, Ping, Lihou, Christine F, Zhen, Huiling, Asatiani, Ekaterine, Féliz, Luis, Vogel, Arndt
Publicado 2020